ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Core Viewpoint - ReShape Lifesciences has announced a public offering of 2,575,107 units at a price of $2.33 per unit, aiming to raise approximately$6.0 million before expenses [1][2]. Group 1: Offering Details - Each unit in the offering consists of one common share (or a pre-funded warrant) and one warrant to purchase one common share [1]. - The warrants are initially exercisable at $5.83 per share and are subject to adjustments for dividends and splits, with a one-time reset on a specified date [2]. - The offering is expected to close on or about February 18, 2025, pending customary closing conditions [2]. Group 2: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band systems and the ReShape Diabetes Neuromodulation system [6]. - The company provides minimally invasive treatments for obesity and metabolic diseases, positioning itself as an alternative to more invasive surgical procedures [6].